Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stanford VI for Advanced Hodgkin's Disease
NCT00225173Phase 2
Key facts
- Status
- Terminated
- Start
- Oct 2001
- Primary completion
- Sep 2005
- Countries
- 1
- Sponsor
- Stanford University
- Modality
- Small Molecules
- Conditions
- Hodgkin lymphoma (HL)
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and vinorelbine in Hodgkin lymphoma (HL), sponsored by Stanford University. Primary endpoint: Freedom from progression. Started Oct 2001; status: terminated.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Stanford VI
Chemotherapy weekly for 19 weeks followed by conditional irradiation
03
Who it enrols
Untreated, locally extensive or advanced stage classical Hodgkin's disease with 3 or more adverse risk factors.
04
Endpoints
Primary
Freedom from progression
Beyond the preview
Go deeper on NCT00225173.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00225173.